Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

The Journal of antimicrobial chemotherapy - 1 Apr 2006

Rodés Berta, Sheldon Julie, Toro Carlos, Jiménez Victoria, Alvarez Miguel Angel, Soriano Vincent

Abstract excerpt

BACKGROUND: Current protease inhibitors (PIs) are designed against HIV-1, and information on their performance against HIV-2 clinical isolates is scarce. METHODS: Genetic and phenotypic analyses using all available PIs were performed in five HIV-2 primary isolates from two patients on regular follow-up who failed PI-HAART. RESULTS: HIV-2 proteases before therapy showed amino acids associated with resistance in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to Microbial Sensitivity Tests

Share to Sequence Analysis, DNA

Share to Treatment Failure

Source

Identifiers

PMID: 16464891
DOI: 10.1093/jac/dkl034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.PMID 16464891Read ↗

HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.Semantic proximity Read ↗

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.Semantic proximity Read ↗

In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.Semantic proximity Read ↗

Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.Semantic proximity Read ↗

Navigating HIV-1 drug resistance: A comprehensive review of protease inhibitor efficacy and mutation dynamics.Semantic proximity Read ↗

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.Semantic proximity Read ↗

Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.Semantic proximity Read ↗

Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.Semantic proximity Read ↗

Determining and overcoming resistance to HIV protease inhibitors.Semantic proximity Read ↗

Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.Semantic proximity Read ↗

Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.Semantic proximity Read ↗

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.